Zachée P, Ferrant A, Daelemans R, Goossens W, Boogaerts M A, Lins R L
Department of Hematology, University Hospital Gasthuisberg, Leuven, Belgium.
Nephron. 1995;71(3):343-9. doi: 10.1159/000188741.
In 4 chronic hemodialysis patients we have tested whether the administration of reduced glutathione (GSH; Glutamed, Boehringer Mannheim Italia; 1,200 mg i.v.) at the end of each hemodialytic session during 90 days could minimize oxidative damage to the red blood cells (RBC) and reduce the recombinant human erythropoietin requirements. Treatment with GSH was followed by an increase in RBC GSH content (n = 3), a normalization of the ascorbine cyanide test (n = 4), an increase in RBC survival (n = 3), and a reduction in 2 patients of the erythropoietin need (41 and 26%, respectively, after 3 months of therapy). When the GSH supplements were terminated, we noticed after 3 months a re-establishment of the baseline values. On the other hand, malonyldialdehyde, RBC deformability, and RBC splenic pool were abnormal before and remain abnormal during the test period. Since no adverse reactions were noticed, these findings seem to indicate the GSH could ameliorate the intraerythrocytic oxidative defense and could be as useful drug in the treatment of anemia in patients affected by chronic renal failure.
在4例慢性血液透析患者中，我们测试了在90天内每次血液透析结束时给予还原型谷胱甘肽（GSH；意大利勃林格殷格翰公司的Glutamed；静脉注射1200mg）是否能将对红细胞（RBC）的氧化损伤降至最低，并减少重组人促红细胞生成素的需求量。给予GSH治疗后，红细胞内谷胱甘肽含量增加（n = 3），抗坏血酸氰化物试验恢复正常（n = 4），红细胞存活率提高（n = 3），2例患者的促红细胞生成素需求量减少（治疗3个月后分别减少41%和26%）。当停止补充GSH后，3个月后我们注意到各项指标又恢复到了基线值。另一方面，丙二醛、红细胞变形性和红细胞脾池在试验前就异常，且在试验期间一直保持异常。由于未观察到不良反应，这些发现似乎表明GSH可改善红细胞内的氧化防御，可能是治疗慢性肾衰竭患者贫血的一种有用药物。
